glp-1 agonists drug class receptor Glucagon-like peptide-1 - Wikipedia

Description

doi: 10.7759/cureus.51151

A phase II trial is underway in the United States (NCT06916065) to evaluate tolerance and side effects 11

2024;387:e080340

95% CI, 0.820.92).[21] Another study revealed that semaglutide and tirzepatide were promising potential therapies in patients with obesity and comorbid alcohol use disorder,[56, 57] and dulaglutide use for smoking cessation did not improve tobacco abstinence but did reduce alcohol consumption.[58, 59] Studies of exenatide reported improved smoking cessation outcomes, though no benefit was observed for cocaine or alcohol use.[6062] A comparative study found semaglutide associated with a significantly lower hazard ratio for nicotine use versus sitagliptin, empagliflozin, and glipizide.[63] Additional GLP-1RA uses Emerging off-label indications for GLP-1RAs continue to be identified, with future research potentially establishing a basis for their extended therapeutic application in a range of medical conditions